Ultragenyx Pharmaceutical (RARE) Retained Earnings (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Retained Earnings of -$4.7 billion for Q1 2026, down 14.83% year-over-year from -$5.5 billion in Q1 2025, and down 471800.0% on a QoQ basis from $1.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 14 years of Retained Earnings data on file, last reported at -$4.7 billion in Q1 2026.
- Quarterly Retained Earnings fell 14.83% year-over-year to -$4.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.7 billion (down 14.83% YoY) and the FY2025 annual result came in at $1.0 million, up 100.03% from the prior year.
- Retained Earnings fell to -$4.7 billion in Q1 2026 per RARE's latest filing, from $1.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at $1.0 million in Q4 2025 and bottomed at -$4.7 billion in Q1 2026.
- The 5-year median for Retained Earnings is -$2.2 billion (2022), against an average of -$1.9 billion.
- The widest annual swing landed in 2022, when Retained Earnings plunged 3974958.93%; it then surged 100.03% in 2025.
- Tracing RARE's Retained Earnings over 5 years: stood at -$2.8 billion in 2022, then jumped by 100.02% to $647000.0 in 2023, then sank by 611691.96% to -$4.0 billion in 2024, then surged by 100.03% to $1.0 million in 2025, then plunged by 471800.0% to -$4.7 billion in 2026.
- Per Business Quant, the three latest RARE Retained Earnings figures stand at -$4.7 billion (Q1 2026), $1.0 million (Q4 2025), and -$4.4 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -4.72 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.72 Bn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | -4.40 Bn |
| Jun 30, 2025 | -268,000.00 |
| Mar 31, 2025 | -4.11 Bn |
| Dec 31, 2024 | -3.96 Bn |
| Sep 30, 2024 | -3.82 Bn |
| Jun 30, 2024 | -1.10 Mn |
| Mar 31, 2024 | -3.56 Bn |
| Dec 31, 2023 | 647,000.00 |
| Sep 30, 2023 | -2.24 Mn |
| Jun 30, 2023 | -3.10 Bn |
| Mar 31, 2023 | -3.97 Mn |
| Dec 31, 2022 | -2.78 Bn |
| Sep 30, 2022 | -10.22 Mn |
| Jun 30, 2022 | -8.91 Mn |
| Mar 31, 2022 | -2.23 Bn |
| Dec 31, 2021 | -1.40 Mn |
| Sep 30, 2021 | -1.95 Bn |
| Jun 30, 2021 | -1.88 Bn |
| Mar 31, 2021 | 56,000.00 |
| Dec 31, 2020 | -1.62 Bn |
| Sep 30, 2020 | 1.01 Mn |
| Mar 31, 2020 | -1.55 Mn |
| Dec 31, 2019 | -147,000.00 |
| Sep 30, 2019 | -1.34 Bn |
| Jun 30, 2019 | -1.23 Bn |
| Mar 31, 2019 | -148,000.00 |
| Dec 31, 2018 | -633,000.00 |
| Sep 30, 2018 | -942.46 Mn |
| Jun 30, 2018 | -654,000.00 |
| Mar 31, 2018 | -946,000.00 |
| Dec 31, 2017 | -832.67 Mn |
| Sep 30, 2017 | -750.94 Mn |
| Jun 30, 2017 | -4.22 Mn |
| Mar 31, 2017 | 231,000.00 |
| Dec 31, 2016 | 905,000.00 |
| Sep 30, 2016 | -459.25 Mn |
| Jun 30, 2016 | -394.34 Mn |
| Mar 31, 2016 | -337.42 Mn |
| Dec 31, 2015 | -284.66 Mn |
| Sep 30, 2015 | -229.44 Mn |
| Jun 30, 2015 | -209,000.00 |
| Mar 31, 2015 | -160.42 Mn |
| Dec 31, 2014 | -174,000.00 |
| Sep 30, 2014 | -122.30 Mn |
| Jun 30, 2014 | -48,000.00 |
| Mar 31, 2014 | -92.87 Mn |
| Dec 31, 2013 | -74.84 Mn |